World RNA Series
Upcoming Events in the World RNA Series
We have seen enormous strides in the developments and breakthroughs in RNA-based vaccines, RNA-based therapeutics and targeting RNA fields since the onset of the global pandemic. Keeping pace with the field's rapid advancements, the World RNA Series from Hanson Wade continues to provide unrivaled industry-focused events to help deliver safe and effective RNA therapies to patients faster.
Get a comprehensive overview of the upcoming events within the World RNA Series portfolio below. If you have any questions, get in touch at email@example.com.
Overcome mRNA Process Scale Up & Manufacturing Hurdles towards Regulatory Harmonization by Optimizing In Vitro Transcription, Purification & Analytical Validation of Your mRNA Drug Substance
Harnessing & Engineering the Therapeutic & Functional Delivery Capabilities of Extracellular Vesicles Through Optimized Characterization, Translation & Scale Up Manufacturing for Accelerated Clinical Development
Advance the Targeting of Non-Coding RNAs by Enhancing Target Specificity, Optimizing Formulation & Improving Efficacy for the Accelerated Translation of Safe & Effective Non-Coding RNA Therapeutics into the Clinic
Build Robust Discovery & Pre-Clinical Pipelines of RNA Targeted Small Molecules with Improved Selectivity & Drug-Like Properties for Successful Translation into Clinical Development
Successfully Design & Develop Next-Generation of mRNA-Based Vaccines & Therapeutics with Improved Specificity, Delivery & Efficacy for Immuno-Oncology, Infectious Diseases & Beyond
Accelerating Extrahepatic Delivery, CMC & Clinical Development of Targeted siRNA Therapeutics for Modular, Reproducible & Effective Gene Silencing Therapies Against Oncology, CNS, Rare Diseases & Beyond
Stay Ahead of the Curve with Novel RNA Therapeutics that Offer Exceptional Stability & Durability Whilst Addressing Key Delivery, Pharmacology & Scalability Challenges to Successfully Translate Safe & Effective Next Generation RNA Therapeutics into the Clinic
Successfully Characterizing, Robustly Optimizing Formulation & Advancing the Design of Future Exosome Based, Lipid Nanoparticles & Polymeric-Based Vectors for Targeted Delivery of RNA Vaccines & Therapeutics
Harnessing Disruptive mRNA-Based Technologies to Supercharge Safe, Effective & Globally Accessible Therapeutics & Vaccines in Infectious Diseases, Oncology & Beyond